deltatrials
Completed PHASE2 NCT00048321

ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis

ISIS 104838-CS7, A Double-Blind, Placebo-Controlled, Randomized Trial of the Safety, Efficacy and Pharmacokinetic Profile of ISIS 104838 (TNF-alpha Antisense Oligonucleotide) Subcutaneous Injections in Active Rheumatoid Arthritis Patients

Sponsor: Ionis Pharmaceuticals, Inc.

Conditions Rheumatoid Arthritis
Interventions ISIS 104838
Updated 7 times since 2017 Last updated: Dec 1, 2022 Started: Jan 1, 2002 Primary completion: Feb 1, 2003 Completion: Feb 1, 2003

This PHASE2 trial investigates Rheumatoid Arthritis and is currently completed. Ionis Pharmaceuticals, Inc. leads this study, which shows 7 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Jan 2023 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jan 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ionis Pharmaceuticals, Inc.
Data source: Ionis Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Amarillo, United States, Birmingham, United States, Calgary, Canada, Carrollton, United States, Chicago, United States, Dallas, United States, Decatur, United States, Duncansville, United States, Edmonton, Canada and 21 more location s